The Trump administration has heard the concerns of pro-life organizations and pro-life Americans upset by the news that the FDA had purchased the body parts of aborted babies for research.
In August, shocking revelations proved the Food and Drug Administration signed a new contract to acquire body parts from aborted babies to be transplanted into so-called humanized mice. The grisly experiments allow mice to have a functioning human immune system for research purposes.
Now, the Trump administration has canceled the contract with Advanced Bioscience Resources, a company that buys and sells aborted baby parts from Planned Parenthood and other abortion businesses.
The Health and Human Services department said late Monday that it canceled the contract with the company because it didn’t include “appropriate protections” for fetal tissue procurement. The agency said in a statement that it has “initiated a comprehensive review of all research involving fetal tissue to ensure consistency with statutes and regulations governing such research.”
“After a recent review of a contract between Advanced Bioscience Resources, Inc. and the Food and Drug Administration to provide human fetal tissue to develop testing protocols, HHS was not sufficiently assured that the contract included the appropriate protections applicable to fetal tissue research or met all other procurement requirements. As a result, that contract has been terminated, and HHS is now conducting an audit of all acquisitions involving human fetal tissue to ensure conformity with procurement and human fetal tissue research laws and regulations. In addition, HHS has initiated a comprehensive review of all research involving fetal tissue to ensure consistency with statutes and regulations governing such research, and to ensure the adequacy of procedures and oversight of this research in light of the serious regulatory, moral, and ethical considerations involved. Finally, HHS is continuing to review whether adequate alternatives exist to the use of human fetal tissue in HHS funded research and will ensure that efforts to develop such alternatives are funded and accelerated.”